New York’s legal cannabis rollout was built on a bold promise: equity. The state’s Conditional Adult-Use Retail Dispensary (CAURD) program was designed to give people impacted by the War on Drugs the first opportunity to legally operate cannabis businesses. But the recent **$2.5 million lawsuit involving Leeann Mata , owner of the Brooklyn dispensary Matawana, is raising difficult questions about how that promise is playing out in reality. The lawsuit, filed by Housing Works , alleges that Mata owes millions in unpaid fees tied to assistance provided during the launch of her dispensary. Housing Works was one of the early organizations involved in helping New York’s first wave of licensed cannabis retailers get off the ground. According to the complaint, their support—ranging from operational help to development services—created financial obligations that remain unresolved. Mata, however, disputes the claims and has pushed back publicly. She argues that the partnership became complicated and that the system itself placed equity license holders in extremely difficult positions. Like many early operators, she had to navigate high startup costs, limited access to traditional financing, and an evolving regulatory landscape. The case is about more than one dispensary. It highlights the growing pains of New York’s cannabis market and the tension between policy ideals and real-world business pressures. The CAURD program aimed to correct decades of harm caused by cannabis prohibition, but many license holders have faced delays, financial hurdles, and complicated partnerships while trying to open their doors. For New York’s cannabis industry, this lawsuit represents a broader question: how do you build a fair market while also creating sustainable businesses? The answer isn’t simple. Legal operators must deal with heavy regulation, taxes, and intense competition from the still-massive illicit market. At the same time, equity entrepreneurs often start with fewer resources and more obstacles than traditional investors. What’s clear is that New York cannabis is still evolving. Lawsuits like this reveal the structural challenges that remain beneath the surface of legalization headlines. For consumers and operators alike, it’s a reminder that the cannabis industry isn’t just about products and storefronts—it’s about policy, power, and the long road toward a truly equitable marketplace. By Justice — Elevated Club NYC

By Justice — Elevated Club NYC New York’s cannabis market just got another reminder that legalization is still a work in progress. Recently, the New York State Office of Cannabis Management  (OCM) announced a precautionary recall of dozens of cannabis product lots after discovering unreliable testing results from a licensed laboratory. The issue centers around a testing facility called Keystone State Testing New York , which regulators say reported inaccurate results on safety screenings. In total, 55 product lots were recalled, including flower, pre-rolls, edibles, and beverages that had already made their way onto dispensary shelves across the state. The concern isn’t necessarily that the cannabis itself was confirmed to be unsafe — the problem is that the lab data cannot be trusted. According to regulators, 54 product lots were incorrectly reported as passing tests for Aspergillus, a potentially harmful mold that can pose risks to consumers with weakened immune systems. Another lot reportedly had incorrect results related to cadmium, a heavy metal that cannabis products are required to screen for. So the state did what regulators are supposed to do: pause, investigate, and recall the affected batches until their safety can be verified. For consumers, this might sound alarming. But in reality, recalls like this are part of how regulated markets are supposed to function. Unlike the unregulated market of the past, licensed cannabis in New York must pass strict lab testing before reaching consumers. Still, this situation highlights a bigger conversation happening across the cannabis industry: lab reliability and oversight. Testing labs hold enormous influence over the supply chain. They determine potency levels, pesticide compliance, mold safety, and heavy metal thresholds. When lab data is inconsistent or unreliable, it can affect cultivators, processors, retailers, and ultimately the consumer. For New York’s young cannabis market, moments like this are part of the growing pains of building a regulated system. Transparency matters. Accountability matters. And most importantly, consumer trust matters. At Elevated Club NYC, we believe cannabis consumers deserve clarity about what they’re buying and confidence in the systems meant to protect them. Education is elevation — and staying informed about industry developments is part of being a responsible consumer in this new era of legal cannabis. The takeaway isn’t panic. The takeaway is progress. Because a system that identifies problems and addresses them openly is ultimately a system moving in the right direction. Stay informed. Stay elevated.lol l

By Justice – Elevated Club NYC A new report from Children’s National Hospital in Washington, D.C., is drawing attention to a growing issue in the cannabis conversation: an increase in teenagers and even younger children seeking treatment for cannabis use and dependency. According to doctors at the hospital, some patients being treated for cannabis addiction are as young as 11 years old, with many cases coming from middle- and high-school students. The hospital’s addiction program says the shift has become noticeable over the last few years. When the clinic first opened in 2022, most young patients were seeking help for opioids like fentanyl. Recently, however, those cases have declined while cannabis-related cases have increased, bringing more families to emergency rooms, pediatricians, and addiction clinics looking for help. One of the biggest factors doctors point to is potency. Cannabis products today are far stronger than what previous generations experienced. While cannabis plants decades ago typically contained 1–5% THC, modern flower often reaches 20–25% THC, and some vape cartridges can contain up to 70% THC. That difference matters, especially for developing brains. Medical professionals warn that strong cannabis exposure during adolescence may increase the risk of mental health issues such as psychosis or bipolar disorder. Young users are also sometimes hospitalized for cannabinoid hyperemesis syndrome, a condition that causes severe vomiting and dehydration after repeated cannabis use. Another concern is how easy modern cannabis products are to conceal. Vape pens and cartridges often resemble everyday objects like highlighters or gaming accessories, making them difficult for parents and teachers to identify. Because these products produce less odor than traditional cannabis, many adults underestimate how common they are among teens. But the story is more complicated than headlines suggest. Cannabis remains one of the most widely used substances among teenagers, and research shows that early exposure increases the likelihood of developing a cannabis use disorder later in life. At the same time, legal markets were designed to create safer systems — including age verification, lab testing, and regulated retail environments. For the cannabis industry, stories like this highlight an important responsibility. Legal operators, educators, and policymakers all play a role in ensuring that cannabis remains an adult product. That means responsible marketing, clear labeling, and continued education about potency and safe consumption. At Elevated Club NYC, we believe legalization isn’t just about access — it’s about structure, accountability, and education. The conversation around cannabis needs nuance. Yes, the plant has legitimate adult uses and benefits. But like alcohol or any psychoactive substance, it also carries risks — especially for young people whose brains are still developing. The takeaway isn’t panic. It’s awareness. If the cannabis industry wants to continue evolving responsibly, the focus must remain clear: keep cannabis out of the hands of minors while educating adults about how to use it responsibly. Because elevation should always come with understanding. Education is elevation. — Justice Elevated Club NYC

By Justice | Elevated Club NYC In 2020, Jay-Z  entered the cannabis space with intention. Not loudly. Not recklessly. Intentionally. His brand, Monogram , positioned itself as a luxury offering — curated flower, refined packaging, elevated pricing, and a design language that felt closer to fashion than traditional cannabis retail. It wasn’t meant to compete with discount eighths. It was meant to reframe the category. Monogram launched in partnership with Caliva , which later became part of The Parent Company , a publicly traded cannabis venture that promised scale, capital strength, and cultural impact. On paper, the structure made sense. Celebrity influence paired with operational infrastructure. But cannabis is not fashion. And it is not music. The California market became one of the most competitive in the country — heavy taxation, oversupply, price compression, and a growing illicit market that undercut legal pricing. Consumers shifted toward value. Margins tightened. Public cannabis stocks declined sharply across the board. Luxury alone couldn’t offset market realities. By late 2022, Jay-Z stepped back from active involvement as The Parent Company reported significant financial strain. Restructuring followed. Mergers followed. Visibility around Monogram softened. The brand didn’t explode — it receded. But this isn’t a failure story. It’s a market lesson. Celebrity can open the door. It cannot stabilize supply chains. Branding can elevate perception. It cannot eliminate tax burdens. Cultural relevance can create buzz. It cannot guarantee velocity at retail. Cannabis rewards discipline. Pricing strategy. Distribution control. Regulatory awareness. Operational strength. At Elevated Club NYC, we watch these moves carefully. The lesson isn’t that luxury doesn’t work — it’s that luxury must be supported by infrastructure. The brands that endure are the ones that balance identity with economics. Monogram proved something important: cannabis is powerful, but it is also unforgiving. The market humbles hype quickly. And in this industry, precision matters more than prestige. Education is elevation. — Justice Elevated Club NYC Quick. Easy. Discreet.

By Justice – Elevated Club NYC For years, cannabis conversations were dominated by one question: “How strong is it?” Higher THC. Bigger hits. Louder effects. Now the conversation is shifting. Microdosing — taking very small, controlled amounts of cannabis — is becoming one of the most intentional ways adults are incorporating it into their lifestyle. And gummies make that precision easier than ever. What Is Microdosing? Microdosing typically means consuming between 1–5mg of THC at a time. The goal isn’t to feel “high” in the traditional sense. It’s to create a subtle shift — a lift in mood, a softening of stress, a gentle creative push — without overwhelming your clarity or productivity. Think of it as calibration, not escape. Why Gummies? Gummies allow for measured consistency. Unlike smoking, where dosage can vary, edibles are labeled by milligram. You know what you’re taking. You can start low. You can scale slowly. That control matters. Because with edibles, patience is part of the ritual. Effects can take 30–90 minutes to fully settle in. Microdosing works best when you respect the timeline. Take a small amount. Wait. Observe. Adjust next time — not immediately. The Long Game Many adults are exploring microdosing as part of a balanced routine — for creative focus, social ease, evening wind-down, or simply to take the edge off a long NYC day. The key is intention. More isn’t better. Better is better. At Elevated Club NYC, we believe education is elevation. Understanding your tolerance, your environment, and your purpose changes the experience entirely. Cannabis isn’t one-size-fits-all — and microdosing reflects that maturity in the culture. Start low. Stay aware. Move with intention. Discreet. Seamless. Elevated.

By Justice Elevated Club NYC New York might be preparing for another shift in the cannabis industry — and this one could land in the beverage aisle. A proposal moving through the New York State Legislature would allow licensed liquor and wine stores to sell low-dose THC beverages. If passed, this would mark a significant expansion beyond dispensaries, potentially placing cannabis drinks alongside wine, spirits, and craft beer. Let’s break down what that actually means. What’s Being Proposed? The legislation would permit liquor stores to sell cannabis-infused beverages containing limited amounts of THC — typically around 5mg per serving. These products would remain restricted to adults 21+ and would require additional licensing and compliance measures for participating retailers. Right now, THC drinks in New York can only be sold through licensed cannabis dispensaries. This proposal changes that distribution channel — not the age restrictions, not the compliance requirements, and not the regulatory oversight. Why Cannabis Beverages? Cannabis drinks are one of the fastest-growing categories in the industry. Consumers are increasingly choosing beverages for: • Measured dosing • Smoke-free consumption • Social settings • Familiar format (like seltzers or cocktails) For many adults, a 5mg THC seltzer feels more approachable than a pre-roll or edible. It’s discreet. Controlled. Predictable. Sound familiar? What This Means for NYC If liquor stores gain access to THC beverages, the cannabis market becomes more normalized — and more competitive. Wider retail access could: • Increase consumer awareness • Expand brand competition • Push innovation in beverage formulations • Raise new compliance questions It also blurs a cultural line that’s existed for decades — alcohol on one shelf, cannabis in another space entirely. New York has always been a market leader. If this passes, it could influence how other states approach THC beverage regulation nationwide. The Bigger Conversation This isn’t just about drinks. It’s about distribution power. Who controls shelf space? Who controls consumer access? How do regulators maintain safety and education while expanding availability? Legal markets were designed to create structure — lab testing, age verification, tax revenue, accountability. If access expands, those guardrails matter even more. At Elevated Club NYC, we believe education is elevation. Whether cannabis stays in dispensaries or moves into broader retail channels, informed consumers win. Where Things Stand The proposal is still under review. Nothing has changed yet. Liquor stores cannot currently sell THC beverages under New York law. But the conversation is happening — and in this industry, conversations often turn into policy. New rules. New market. We’re watching closely. Stay Elevated. NYC • 21+ • Valid ID Required Elevated Club NYC Quick. Easy. Discreet.

The United States Supreme Court is preparing to hear a case that could reshape the intersection of cannabis policy and constitutional rights nationwide. At the center is United States v. Hemani, a challenge to a federal statute — 18 U.S.C. § 922(g)(3) — that prohibits “unlawful users” of controlled substances from possessing firearms. Because cannabis remains federally illegal, marijuana consumers — even in fully legal states — can fall into that category. That’s where the tension begins. Today, the majority of Americans live in states where cannabis is legal for medical or adult use. Dispensaries operate openly. Products are lab tested. Taxes are collected. Regulation exists. Yet under federal law, cannabis is still classified as a controlled substance. So the question becomes: Can someone comply with state cannabis laws and still be barred from exercising federal constitutional rights? The Supreme Court’s modern Second Amendment framework, established in 2022, requires firearm restrictions to align with America’s historical tradition of regulation. Lower courts have disagreed on how that applies to cannabis consumers. Some argue the government may disarm groups considered “dangerous.” Others question whether occasional marijuana use qualifies someone as a public safety threat at all. Adding another layer, the Department of Justice has argued that even if cannabis is rescheduled under federal law, the firearm prohibition should remain in place. In other words, reclassification wouldn’t automatically restore gun rights for users. This case isn’t simply about guns or cannabis. It’s about federal authority, evolving drug policy, and how constitutional interpretation adapts to cultural change. It forces the country to confront a broader reality: legalization at the state level does not erase federal consequences. For those of us operating in legal markets like New York, understanding that distinction matters. Policy shifts ripple beyond storefronts and supply chains — they affect civil liberties, compliance decisions, and public perception. Education is elevation. Whatever the Court decides will set a precedent that reaches far beyond one individual case. And in an industry evolving as rapidly as cannabis, staying informed isn’t optional — it’s essential.

By Justice, Elevated Club NYC This week, a jury in Nebraska  found former notary Jacy Todd  guilty on all 24 criminal charges tied to medical cannabis ballot petitions. The verdict came out of Hall County , where prosecutors argued that required notarization procedures were not properly followed during the signature collection process. Let’s be clear: this case wasn’t about whether patients deserve access to medical cannabis. Nebraska voters already answered that when they approved Initiative 437  in 2024. This case was about process — specifically, whether petition affidavits were legally notarized in accordance with state law. Prosecutors, including representatives from the Nebraska Attorney General’s Office , framed the issue as one of election integrity. Their argument: if the rules around petition verification aren’t followed, the legitimacy of the ballot itself can be questioned. The defense signaled plans to appeal, raising legal questions about how notaries are classified and what level of intent must be proven. Why does this matter beyond Nebraska? Because cannabis reform doesn’t just live or die on public support — it lives or dies on compliance. Every signature. Every affidavit. Every procedural step. When movements cut corners (intentionally or not), opponents of legalization use those missteps to challenge the broader cause. For the cannabis industry nationwide, this is a reminder: legalization is no longer fringe activism. It’s policy. And policy requires precision. At Elevated Club NYC, we talk a lot about standards. Lab testing. Transparency. Compliance. The same principle applies here. Reform without structure invites resistance. Reform with integrity builds staying power. Nebraska voters spoke. Medical cannabis passed. But the legal battles around process show how fragile progress can be when technicalities enter the conversation. The bigger takeaway? Cannabis reform has matured. It’s no longer just cultural — it’s constitutional. It intersects with election law, criminal law, administrative rules, and regulatory oversight. And that means the movement must operate at the highest level. Education is elevation. 🌿 Stay informed. Stay compliant. Stay elevated.

A recent report highlighted by News-Medical.net  examined new research showing that teen cannabis use trends closely mirror long-established alcohol consumption patterns. That comparison isn’t random — it’s structural. Researchers found that when overall cannabis use rises among adolescents, it doesn’t just increase among heavy users. It increases across the entire group. And when it declines, it declines broadly. This mirrors what public-health experts call the “total consumption model,” long used in alcohol research. The idea is simple: shifts in the average affect everyone — from experimental users to frequent ones. Why does that matter? Because it reframes the conversation. For years, cannabis discussions have focused heavily on “problem users.” But if teen usage behaves like alcohol consumption patterns, then broader social norms, availability, peer influence, and cultural messaging play a major role. It’s not just about isolating high-risk individuals — it’s about understanding the environment shaping behavior. As legalization expands and cannabis becomes more normalized in adult spaces, youth perception inevitably shifts. That doesn’t mean legalization causes teen use — research often shows teen usage remaining stable or declining in regulated states — but it does mean cultural signals matter. At Elevated Club NYC, we take this seriously. Legal markets were built around safety, lab testing, age verification, and accountability. The regulated space exists to create structure — not chaos. When products are tested, labeled, and sold responsibly to adults 21+, it reinforces boundaries. Clear compliance protects youth access while ensuring adults have safe options. The bigger lesson here isn’t fear — it’s awareness. Public health data reminds us that consumption trends are social. They move together. They reflect culture. And culture is shaped by education, transparency, and responsible business practices. We can’t talk about cannabis without talking about youth prevention. We can’t talk about normalization without talking about guardrails. Education is elevation. – Justice Elevated Club NYC

By Justice Elevated Club NYC Legal cannabis is supposed to mean safer cannabis. That was the promise. Regulation. Oversight. Transparency. Accountability. We moved from underground markets to licensed storefronts and lab-tested labels because consumers deserve protection — not guesswork. But here’s a question that’s been sitting with me: What are we really testing for? Most state programs require cannabis to be screened for total yeast and mold counts, pesticides, heavy metals, and residual solvents. On paper, that sounds comprehensive. And to be clear — testing is absolutely better than no testing. Legal frameworks have improved safety in many ways. But passing compliance doesn’t always mean passing science. Here’s where the conversation gets uncomfortable. When cannabis tests high for mold, it can fail. That’s good. But in many markets, that batch can be remediated — often through irradiation or other approved processes — and then retested. If the active mold is no longer detectable, it can pass and enter the legal supply chain. Killing mold, however, does not necessarily remove every compound that mold may have produced before it was killed. In food and agricultural industries, certain molds are studied for the toxins they leave behind — mycotoxins. Those compounds can remain even after the organism itself is no longer alive. In cannabis regulation, testing for these specific mold-produced toxins is not universally required. That’s not fear-mongering. That’s chemistry. Now let’s talk about the word that keeps floating around social media: “scromiting.” Severe vomiting episodes often linked to chronic cannabis use are usually discussed under the umbrella of Cannabis Hyperemesis Syndrome (CHS). The common narrative points directly at high potency THC. And maybe potency plays a role. Maybe chronic use plays a role. But are we asking every possible question? If a product fails for mold, gets remediated, passes retesting, and is sold legally — are we certain we’re screening for everything that matters? Or are we screening for what regulations currently require? There’s a difference. This isn’t an anti-cannabis stance. If anything, it’s the opposite. I care about this plant. I care about the culture. I care about the legitimacy of the industry. And legitimacy doesn’t come from silence. It comes from scrutiny. If cannabis wants federal recognition, interstate commerce, and long-term institutional credibility, testing standards will have to evolve alongside the science. Other industries test for specific toxins. Food safety doesn’t stop at surface-level indicators. It drills deeper. Cannabis should be no different. The legal market was built on the idea that regulation equals safety. That’s a powerful promise. But safety isn’t static. It’s iterative. It improves as research improves. It strengthens as standards strengthen. So when I ask, “What are we really testing for?” I’m not attacking operators. I’m not attacking regulators. I’m not attacking consumers. I’m challenging the system to mature. Because legalization wasn’t just about taxes. It wasn’t just about ending prohibition. It was about building something better. Elevated Club NYC has always stood on one principle: elevated by standards, not looks. Flashy packaging doesn’t impress me. High THC numbers don’t impress me. Clean sourcing, transparent testing, and informed consumers — that’s what matters. Education is elevation. Consumers deserve to know: • What is being tested • What is not being tested • What remediation means • What compliance actually covers Trust isn’t built on assumptions. It’s built on information. The cannabis industry is still young. That’s not a weakness — it’s an opportunity. We have the ability to shape it responsibly. To push for better panels. To support deeper research. To demand lab consistency. To welcome hard conversations instead of shutting them down. If we want long-term trust, we have to welcome scrutiny. Legal doesn’t automatically mean perfect. Compliance doesn’t automatically mean comprehensive. And asking better questions doesn’t make you anti-cannabis. It makes you pro-accountability. The culture deserves that. The consumer deserves that. The future of this industry depends on that. What are we really testing for? Stay informed. Stay intentional. Stay Elevated.

By Justice Elevated Club NYC In February 2026, Congress required the U.S. Food and Drug Administration  (FDA) to define what qualifies as a “container” in cannabinoid product regulation and publish a clear list of allowed cannabinoids. That deadline passed. No finalized definitions. No published list. Just silence — and growing frustration across the industry. For a space that’s already navigating patchwork state laws, unclear federal enforcement priorities, and constant compliance shifts, clarity isn’t optional. It’s foundational. Why “Containers” Matter On the surface, defining a “container” may sound technical. But in regulated industries, definitions shape everything: Packaging standards Labeling requirements Storage rules Transportation compliance Enforcement actions If regulators can’t clearly define what a container is, how are businesses supposed to comply with rules tied to that definition? For brands, manufacturers, distributors, and retailers — ambiguity increases legal risk. And risk increases cost. The Missing Cannabinoid List Even more significant is the absence of a finalized list of permitted cannabinoids. The cannabinoid marketplace has expanded far beyond CBD and THC. Consumers now encounter: Delta-8 THC Delta-10 THC THCA HHC CBN CBG Novel synthesized or semi-synthetic variants Without federal clarity, states are left to interpret legality individually. That leads to: Products legal in one state but banned in another Retailers unsure what they can carry Consumers unsure what they’re buying Manufacturers operating in regulatory gray zones That’s not a stable foundation for public health or responsible commerce. Industry Frustration Is Growing Stakeholders argue that Congress mandated action for a reason: safety, standardization, and transparency. When deadlines are missed: Investment slows Compliance costs rise Enforcement becomes inconsistent Illicit markets exploit the uncertainty And we’ve already seen what regulatory confusion creates — unlicensed operators, untested products, and consumers taking risks they don’t fully understand. Legalization was supposed to mean structure, oversight, and accountability. Delays undermine that mission. Public Health vs. Market Reality At Elevated Club NYC, we talk often about education and transparency. Because at the end of the day, this isn’t just about business — it’s about health. Consumers deserve to know: What cannabinoids are permitted What standards products must meet How packaging protects integrity Who is responsible for oversight Federal inaction doesn’t just affect corporations. It affects everyday people trying to make informed decisions. The Bigger Picture Cannabis and hemp policy are at a crossroads in 2026. With rescheduling discussions ongoing and state markets evolving rapidly, federal agencies are under pressure to modernize their frameworks. But modernization requires execution. Clear rules help legitimate operators thrive. Vague rules create chaos. Where We Stand At Elevated Club NYC, we believe: Education is elevation. Clarity protects consumers. Transparency builds trust. Accountability strengthens markets. The industry doesn’t need more gray areas. It needs leadership, structure, and follow-through. The February deadline may have passed — but the need for clear cannabinoid standards hasn’t. Until then, businesses will adapt. Consumers will navigate carefully. And we’ll continue pushing for transparency in a space that deserves better. Stay Elevated.

By Justice, Elevated Club NYC Most people associate cannabis with culture, creativity, medicine, or modern legalization. But long before dispensaries, delivery menus, and compliance labels, cannabinoids were being studied inside classified military labs. During the 1950s and 1960s, at Edgewood Arsenal in Maryland, the U.S. Army Chemical Corps conducted experiments exploring synthetic cannabinoid compounds as potential “nonlethal incapacitating agents.” The idea wasn’t wellness. It wasn’t recreation. It was Cold War strategy. Researchers tested lab-created analogs such as DMHP (dimethylheptylpyran) and later mixtures like EA-2233, both chemically related to THC but engineered to be more potent and longer lasting. Reports from that era suggested extremely small doses could produce intense psychoactive effects — sometimes lasting far longer than traditional cannabis. The goal was simple in theory: temporarily impair enemy forces without destroying infrastructure. A compound that could disorient, disrupt coordination, and reduce morale — without causing permanent harm — was considered strategically valuable. But the science proved unpredictable. Some of these synthetic cannabinoids caused dramatic physiological reactions, including sharp drops in blood pressure. Others lasted too long to be practical. Ultimately, the compounds did not become battlefield tools. But the research left behind an important historical footprint. It’s critical to separate this chapter of history from modern cannabis culture. The plant itself — cultivated, tested, and regulated in today’s legal markets — is not the same as experimental synthetic analogs developed under military research. Lab-made compounds often bind differently to the body’s endocannabinoid receptors and can produce far more extreme or unpredictable effects. Why does this matter today? Because cannabis conversations often lack historical depth. The science didn’t start with legalization. It didn’t start with dispensaries. And it certainly didn’t start with Instagram. It started in laboratories — some medical, some academic, and yes, some military. Understanding this history helps us have smarter conversations about safety, transparency, and responsibility. At Elevated Club NYC, we believe in knowing where your cannabis comes from, how it’s grown, and what’s in it. Education isn’t fear-based — it’s empowering. From classified Cold War research to modern regulated markets, cannabis has traveled a complicated road. And the more we understand that road, the better we navigate where it goes next. Education is elevation. 🌿 — Justice Elevated Club NYC